Role of biochemical Alzheimer’s disease biomarkers as end points in clinical trials

Variations in the neuropathology of familial Alzheimer’s disease

(2009) Claire Shepherd et al.   ACTA NEUROPATHOLOGICA

Measurement of cerebrospinal fluid total tau and phospho-tau in phase 2 trials of therapies targeting Aβ

(2009) Eric R. Siemers et al.   Alzheimers & Dementia

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

Lithium Trial in Alzheimer's Disease

(2009) Harald Hampel et al.   JOURNAL OF CLINICAL PSYCHIATRY

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein  -Secretase for the Treatment of Alzheimer's Disease

(2009) R. L. Martone et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease

(2008) Eric R. Siemers et al.   Alzheimers & Dementia

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

(2008) Claude M. Wischik et al.   Alzheimers & Dementia

In silico modeling system: A national research resource for simulation of complex brain disorders

(2008) Zaven S. Khachaturian et al.   Alzheimers & Dementia

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

The Amyloid-β Rise and γ-Secretase Inhibitor Potency Depend on the Level of Substrate Expression

(2008) Catherine R. Burton et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Amyloid Precursor Protein Trafficking, Processing, and Function

(2008) Gopal Thinakaran et al.   JOURNAL OF BIOLOGICAL CHEMISTRY